首页> 美国卫生研究院文献>Springer Open Choice >Pro-arrhythmogenic Effects of the V141M KCNQ1 Mutation in Short QT Syndrome and Its Potential Therapeutic Targets: Insights from Modeling
【2h】

Pro-arrhythmogenic Effects of the V141M KCNQ1 Mutation in Short QT Syndrome and Its Potential Therapeutic Targets: Insights from Modeling

机译:短QT综合征V141M KCNQ1突变的促心律失常作用及其潜在的治疗靶点:建模的见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gain-of-function mutations in the pore-forming subunit of IKs channels, KCNQ1, lead to short QT syndrome (SQTS) and lethal arrhythmias. However, how mutant IKs channels cause SQTS and the possibility of IKs-specific pharmacological treatment remain unclear. V141M KCNQ1 is a SQTS associated mutation. We studied its effect on IKs gating properties and changes in the action potentials (AP) of human ventricular myocytes. Xenopus oocytes were used to study the gating mechanisms of expressed V141M KCNQ1/KCNE1 channels. Computational models were used to simulate human APs in endocardial, mid-myocardial, and epicardial ventricular myocytes with and without β-adrenergic stimulation. V141M KCNQ1 caused a gain-of-function in IKs characterized by increased current density, faster activation, and slower deactivation leading to IKs accumulation. V141M KCNQ1 also caused a leftward shift of the conductance-voltage curve compared to wild type (WT) IKs (V1/2 = 33.6 ± 4.0 mV for WT, and 24.0 ± 1.3 mV for heterozygous V141M). A Markov model of heterozygous V141M mutant IKs was developed and incorporated into the O’Hara–Rudy model. Compared to the WT, AP simulations demonstrated marked rate-dependent shortening of AP duration (APD) for V141M, predicting a SQTS phenotype. Transmural electrical heterogeneity was enhanced in heterozygous V141M AP simulations, especially under β-adrenergic stimulation. Computational simulations identified specific IK1 blockade as a beneficial pharmacologic target for reducing the transmural APD heterogeneity associated with V141M KCNQ1 mutation. V141M KCNQ1 mutation shortens ventricular APs and enhances transmural APD heterogeneity under β-adrenergic stimulation. Computational simulations identified IK1 blockers as a potential antiarrhythmic drug of choice for SQTS.Electronic supplementary materialThe online version of this article (doi:10.1007/s40846-017-0257-x) contains supplementary material, which is available to authorized users.
机译:IKs通道的孔形成亚基KCNQ1中的功能获得性突变导致短QT综合征(SQTS)和致命性心律失常。然而,突变的IKs通道如何引起SQTS以及IKs特异性药理学治疗的可能性仍不清楚。 V141M KCNQ1是与SQTS相关的突变。我们研究了其对IKs门控特性和人心室肌细胞动作电位(AP)变化的影响。爪蟾卵母细胞用于研究表达的V141M KCNQ1 / KCNE1通道的门控机制。计算模型用于模拟心内膜,心肌中层和心外膜心室肌细胞中有或没有β-肾上腺素能刺激的人类AP。 V141M KCNQ1导致IK中的功能获得,其特征是电流密度增加,激活速度更快,停用速度更慢,从而导致IK积累。与野生型(WT)IK相比,V141M KCNQ1还导致电导-电压曲线向左移动(WT的V1 / 2 = 33.6±4.0 mV,杂合的V141M的24.0±1.3 mV)。开发了杂合V141M突变IK的Markov模型,并将其纳入O'Hara-Rudy模型。与WT相比,AP模拟显示V141M的AP持续时间(APD)明显取决于速率,缩短了SQTS表型。跨壁电异质性在杂合V141M AP模拟中得到增强,尤其是在β-肾上腺素刺激下。计算模拟确定了特定的IK1阻断作为减少与V141M KCNQ1突变相关的跨壁APD异质性的有益药理学目标。 V141M KCNQ1突变缩短了心室AP并增强了β-肾上腺素刺激下的跨壁APD异质性。计算模拟确定IK1阻滞剂是SQTS的潜在抗心律不齐药物选择。电子补充材料本文的在线版本(doi:10.1007 / s40846-017-0257-x)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号